Thieler Law Corp advises investors with losses exceeding $100,000 of the August 23, 2019 lead plaintiff deadline in a class action lawsuit filed against Teva Pharmaceutical Industries Ltd (NYSE: TEVA) (“Teva” or “the Company”). The suit is pending in the U.S. District Court for the Eastern District of Pennsylvania and investors, who purchased Teva Pharmaceutical Industries Ltd securities between August 4, 2017 and May 10, 2019, have until August 23, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Teva Pharmaceutical Industries Ltd securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

On May 10, 2019, an alliance of 44 states filed an antitrust complaint exposing previously undisclosed facts about Teva’s participation in the generic drug price-fixing conspiracy. According to the complaint, Teva’s role was described as a “consistent participant” in the conspiracy, implementing price increases for more than 110 generic drugs and plotting with other drug companies for over 85 different generic drugs. 

On this news, NYSE: TEVA fell $2.13 per share or roughly 15%, to close at $12.23 on May 13, 2019.  

If you were negatively impacted by your investment in Teva Pharmaceutical Industries Ltd securities between August 4, 2017 and May 10, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185